Retrophin, Inc. Uncategorized Contracts & Agreements
15 Contracts & Agreements
- Amendment No. 5 to Sublicense Agreement, dated as of March 20, 2018, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on October 31, 2024)
- Amended and Restated Open Market Sale Agreement, dated October 31, 2024, by and between the Company and Jefferies LLC (Filed With SEC on October 31, 2024)
- The Company's 202 (Filed With SEC on February 20, 2024)
- Amendment No. 4 to Sublicense Agreement dated as of September 17, 2015, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on February 24, 2022)
- Amendment No. 3 to Sublicense Agreement dated as of February 27, 2015, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on February 24, 2022)
- Amendment No. 5 to Sublicense Agreement dated as of March 20, 2018, between the Company and Ligand Pharmaceuticals Incorporated (Filed With SEC on May 1, 2018)
- Form of Indemnity Agreement (Filed With SEC on May 1, 2018)
- AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (Filed With SEC on November 6, 2015)
- AMENDMENT NO. 3 TO SUBLICENSE AGREEMENT (Filed With SEC on May 11, 2015)
- Summary SeparationProposal (Filed With SEC on March 11, 2015)
- SPONSORED RESEARCH AGREEMENT (Filed With SEC on December 18, 2013)
- SPONSORED RESEARCH AGREEMENT (Filed With SEC on December 5, 2013)
- [MSMB LETTERHEAD] (Filed With SEC on November 15, 2013)
- SPONSORED RESEARCH AGREEMENT (Filed With SEC on November 15, 2013)
- SUBLICENSE AGREEMENT (Filed With SEC on December 19, 2012)
